We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
What Does the Future Hold for PI3K/AKT/ mTOR Inhibitors in Breast Cancer?
- Authors
Peddi, Parvin F.; Hurvitz, Sara A.
- Abstract
The PI3K/Akt/mTOR pathway has been clearly established as a key regulator of cell growth, metabolism and survival. Its dysregulation, on the other hand, has been implicated in tumorogenesis of various malignancies, including breast cancer, with up to one half of certain types of breast cancers harboring mutations of this pathway. Research has also shown that mutations of this pathway can cause resistance to targeted therapies such as endocrine or anti-HER2 therapies. Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, is the most recently approved drug for breast cancer and appears to re-sensitize ER+ positive breast cancer to endocrine therapy. Various other drugs targeting this pathway are in development in breast cancer, including hormone receptor positive, HER2 amplified, and triple negative breast cancers.
- Publication
Journal of OncoPathology, 2013, Vol 1, Issue 4, p73
- ISSN
2052-5931
- Publication type
Academic Journal
- DOI
10.13032/tjop.2052-5931.100069